Electronic cigarettes, or e-cigarettes, are battery-powered devices that provide doses of nicotine and other additives to the user in an aerosol. Depending on the brand, e-cigarette cartridges typically contain nicotine, a component to produce the aerosol (e.g., propylene glycol or glycerol), and flavorings (e.g., fruit, mint, or chocolate) (1) . Potentially harmful constituents also have been documented in some e-cigarette cartridges, including irritants, genotoxins, and animal carcinogens (1) . E-cigarettes that are not marketed for therapeutic purposes are currently unregulated by the Food and Drug Administration, and in most states there are no restrictions on the sale of e-cigarettes to minors. Use of e-cigarettes has increased among U.S. adult current and former smokers in recent years (2); however, the extent of use among youths is uncertain.
Data from the 2011 and 2012 National Youth Tobacco Survey (NYTS), a school-based, pencil-and-paper questionnaire given to U.S. middle school (grades 6-8) and high school (grades 9-12) students, were used to estimate the prevalence of ever and current (≥1 day in the past 30 days) use of e-cigarettes, ever and current (≥1 day in the past 30 days) use of conventional cigarettes, and use of both. NYTS consists of a cross-sectional, nationally representative sample of students in grades 6-12 from all 50 states and the District of Columbia (3).
During 2011-2012, among all students in grades 6-12, ever e-cigarette use increased from 3.3% to 6.8% (p<0.05) (Figure) ; current e-cigarette use increased from 1.1% to 2.1% (p<0.05), and current use of both e-cigarettes and conventional cigarettes increased from 0.8% to 1.6% (p<0.05). In 2012, among ever e-cigarette users, 9.3% reported never smoking conventional cigarettes; among current e-cigarette users, 76.3% reported current conventional cigarette smoking.
Among middle school students, ever e-cigarette use increased from 1.4% to 2.7% during 2011-2012 (p<0.05) (Figure) ; current e-cigarette use increased from 0.6% to 1.1% (p<0.05), and current use of both e-cigarettes and conventional cigarettes increased from 0.3% to 0.7% (p<0.05). In 2012, among middle school ever e-cigarette users, 20.3% reported never smoking conventional cigarettes; among middle school current e-cigarette users, 61.1% reported current conventional cigarette smoking.
Among high school students, ever e-cigarette use increased from 4.7% to 10.0% during 2011-2012 (p<0.05) (Figure) ; current e-cigarette use increased from 1.5% to 2.8% (p<0.05), and current use of both e-cigarettes and conventional cigarettes increased from 1.2% to 2.2% (p<0.05). In 2012, among high school ever e-cigarette users, 7.2% reported never smoking conventional cigarettes; among high school current e-cigarette users, 80.5% reported current conventional cigarette smoking.
E-cigarette experimentation and recent use doubled among U.S. middle and high school students during 2011-2012, resulting in an estimated 1.78 million students having ever used e-cigarettes as of 2012. Moreover, in 2012, an estimated 160,000 students who reported ever using e-cigarettes had never used conventional cigarettes. This is a serious concern because the overall impact of e-cigarette use on public health remains uncertain. In youths, concerns include the potential negative impact of nicotine on adolescent brain development (4), as well as the risk for nicotine addiction and initiation of the use of conventional cigarettes or other tobacco products.
CDC and the Food and Drug Administration will continue to explore ways to increase surveillance and research on e-cigarettes. Given the rapid increase in use and youths' susceptibility to social and environmental influences to use tobacco, developing strategies to prevent marketing, sales, and use of e-cigarettes among youths is critical. 
Errata
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In the Recommendations and Reports, "Diagnosis and Management of Q Fever -United States, 2013: Recommendations from CDC and the Q Fever Working Group" on page 6, in Table 2 , the following errors occurred.
In the third column, "Children," the recommended treatment of acute Q fever for children aged <8 years with mild or uncomplicated illness, should read as follows: "Doxycycline 2.2 mg/kg per dose twice a day for 5 days (maximum 100 mg per dose). If patient remains febrile past 5 days of treatment: trimethoprim/sulfamethoxazole 4-20 mg/kg/24 hours (dose based on trimethoprim component) in equally divided doses every 12 hours (maximum: 320 mg trimethoprim per 24 hours)"
In the fourth column, "Pregnant women," the recommended treatment of acute Q fever for pregnant women should read as follows: "Trimethoprim/sulfamethoxazole: 160 mg/800 mg twice a day throughout pregnancy but not beyond 32 weeks' gestation † † In the ¶ footnote, the following sentence should be added at the end: "Trimethoprim/sulfamethoxazole is contraindicated in children aged <2 months."
In the † † footnote, the following sentence should be added at the end: "Trimethoprim/sulfamethoxazole should be discontinued for the final 8 weeks of pregnancy because of the risk for hyperbilirubinemia."
Announcement
Laboratory Quality Improvement Tutorial Available from CDC
Application of Laboratory Medicine Best Practices (LMBP) Initiative A-6 Methods for Laboratory Practitioners, a free, online continuing education course, is now available from CDC. This 1-hour tutorial provides a model for the stepwise design and implementation of quality improvement studies, including how these studies can advance evidence-based laboratory medicine. The format presents access to published journal articles, project planning templates, and informative websites. The course is available at https://www.futurelabmedicine.org/tutorials.
